SEGMENT REPORTING

12 Months Ended

Dec. 31, 2012

SEGMENT REPORTING [Text Block]

17. SEGMENT REPORTING

As defined in ASC Topic 280, “Segment Reporting”, the Company has three operating segments, and two reportable segments, including Chaoying Biotech and SD Chaoying. Chaoying Biotech is primarily in the business of researching, producing, and selling of high-quality tissue arrays and providing related services. SD Chaoying mainly focused on real estate development and intended to operate a cultural and entertainment center which will encompass a wide variety of recreational and commercial activities. Earnings performance is measured using segment operating income.

		Years Ended December 31,
		2012		2011
Revenues:
Chaoying Biotech	$	514,593	$	552,811
SD Chaoying		268,582		(6,553	)
Others		-		-
Total Revenues	$	783,175	$	546,258

		Years Ended December 31,
		2012			2011
Segment loss:
Chaoying Biotech	$	(121,753	)	$	(252,126	)
SD Chaoying		(304,170	)		(253,153	)
Others		(229,717	)		(233,874	)
Loss before Income Taxes	$	(655,640	)	$	(739,153	)

		Years Ended December 31,
		2012		2011
Total Assets:
Chaoying Biotech	$	1,460,233	$	1,507,130
SD Chaoying		9,006,220		9,276,414
Others		85,055		127,978
Total assets	$	10,551,508	$	10,911,522

The following sets forth geographic information relating to the Company’s revenues from external customers attributed to the Company’s country of domicile, China, and attributed to foreign countries.

		Years Ended December 31,
		2012		2011
United States	$	450,042	$	502,983
China		333,133		43,275
Total revenue	$	783,175	$	546,258

All revenues are from external customers. One major customer from the United States accounted for 57% and 92% of our total revenues for the years ended December 31, 2012 and 2011. All long-lived assets are located in China.